News
STAT+: Doudna talks cost, access issues looming over first CRISPR therapy
“How do we make sure that a technology like CRISPR — you know, no offense intended — is not just going to make a few people rich, but it’s going… […]
life sciences
News
Listen: Lilly’s Alzheimer’s success, a milestone FDA approval, & Moderna’s shrinking business
What’s the future of Alzheimer’s disease treatment? How do you pivot from a pandemic? And how successful can Wegovy get? Find out on the new episode of “The Readout LOUD.” […]
News
STAT+: Gilead foresees more growth in its HIV drugs
Gilead’s CEO believes the foundation of the company will continue to be its HIV franchise, particularly PrEP. #STATBreakthrough […]
News
For Eli Lilly’s head scientist, Alzheimer’s results cap a 25-year scientific quest
“Probably any words I use to describe my emotions at seeing this data will understate it,” said Daniel Skovronsky, Eli Lilly’s head scientist. […]
News
STAT+: The CEO of 23andMe says people are willing to share health data — if ‘treated like adults’
23AndMe CEO Anne Wojcicki was among the health data experts who convened to discuss the future of patient privacy at a panel this week. […]
News
STAT+: The CEO of 23andMe says people are willing to share health data — if ‘treated like adults’
23AndMe CEO Anne Wojcicki was among the health data experts who convened to discuss the future of patient privacy at a panel this week. […]
